You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 6,242,187


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,242,187
Title: Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
Abstract:This invention provides a method for determining susceptibility for an anti-viral drug comprising: (a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell; (b) culturing the host cell from (a); (c) measuring expression of the indicator gene in a target host cell; and (d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-viral drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c) This invention also provides a method for determining anti-viral drug resistance in a patient comprising: (a) determining anti-viral drug susceptibility in the patient at a first time using the susceptibility test described above, wherein the patient-derived segment is obtained from the patient at about said time;(b) determining anti-viral drug susceptibility of the same patient at a later time; and (c) comparing the anti-viral drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-viral drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient. This invention also provides a method for evaluating the biological effectiveness of a candidate anti-viral drug compound. Compositions including resistance test vectors comprising a patient-derived segment and an indicator gene and host cells transformed with the resistance test vectors are provided.
Inventor(s): Capon; Daniel J. (Hillsborough, CA), Petropoulos; Christos J. (Half Moon Bay, CA)
Assignee: ViroLogic, Inc. (S. San Francisco, CA)
Application Number:09/371,774
Patent Claims:1. A method for determining susceptibility for an anti-HBV drug comprising:

(a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell;

(b) culturing the host cell from (a);

(c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient- derived seqment; and

(d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-HBV drug, wherein a test concentration of the anti-HBV drug is present at steps (a)-(c); at steps (b)-(c); or at step (c).

2. The method of claim 1 wherein the indicator gene is a non-functional indicator gene.

3. The method of claim 1 wherein the indicator gene is a luciferase gene.

4. The method of claim 1 wherein the indicator gene is an E. coli lacz gene.

5. The method of claim 1 wherein the target host cell is a Jurkat cell line.

6. A resistance test vector comprising a HBV patient-derived segment and an indicator gene.

7. The resistance test vector of claim 6 wherein the indicator gene is a functional indicator gene.

8. The resistance test vector of claim 6 wherein the indicator gene is a non-functional indicator gene.

9. The resistance test vector of claim 6 wherein the indicator gene is a luciferase gene.

10. A packaging host cell transfected with a resistance test vector of claim 6.

11. The packaging host cell of claim 10 that is a mammalian host cell.

12. The packaging host cell of claim 10 that is a human host cell.

13. The packaging host cell of claim 10 that is a human embryonic kidney cell.

14. The packaging host cell of claim 10 that is 293 cells.

15. The packaging host cell of claim 10 that is a human hepatoma cell line.

16. The packaging host cell of claim 10 that is HepG2.

17. The packaging host cell of claim 10 that is Huh7.

18. A method for determining susceptibility for an anti-HBV drug comprising:

(b) introducing a resistance test vector comprising a patient-derived segment and a nonfunctional indicator gene into a host cell;

(b) culturing the host cell from (a);

(c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient- derived segment; and

(d) comparing the expression of the indicator gene from (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the anti-HBV drug, wherein a test concentration of the anti-HBV drug is present at steps (a)-(c); at steps (b)-(c); or at step (c).

19. The method of claim 18 wherein the nonfunctional indicator gene comprises a permuted promoter.

20. The method of claim 18 wherein the nonfunctional indicator gene comprises a permuted coding region.

21. The method of claim 18 wherein the nonfunctional indicator gene comprises an inverted intron.

22. The method of claim 18 wherein the host cell and target cell are the same cell.

23. The method of claim 18 wherein the target cell is a human cell.

24. A method for determining anti-HBV drug resistance in a patient comprising:

(a) developing a standard curve of drug susceptibility for an anti-HBV drug;

(b) determining anti-HBV drug susceptibility in the patient according to the method of claim 1; and

(c) comparing the anti-HBV drug susceptibility in step (b) with the standard curve determined in step (a), wherein a decrease in anti-HBV susceptibility indicates development of anti-HBV drug resistance in the patient.

25. A method for determining anti-HBV drug resistance in a patient comprising:

(a) developing a standard curve of drug susceptibility for an anti-HBV drug;

(b) determining anti-HBV drug susceptibility in the patient according to the method of claim 18; and

(c) comparing the anti-HBV drug susceptibility in step (b) with the standard curve determined in step (a), wherein a decrease in anti-HBV susceptibility indicates development of anti-HBV drug resistance in the patient.

26. A method for determining anti-HBV drug resistance in a patient comprising:

(a) determining anti-HBV drug susceptibility in the patient at a first time according to the method of claim 1, wherein the patient-derived segment is obtained from the patient at about said time;

(b) determining anti-HBV drug susceptibility of the same patient at a later time; and

(c) comparing the anti-HBV drug susceptibilities determined in step (a) and (b), wherein a decrease in anti-HBV drug susceptibility at the later time compared to the first time indicates development or progression of anti-viral drug resistance in the patient.

27. A method for determining anti-HBV drug resistance in a patient comprising:

(a) determining anti-HBV drug susceptibility in the patient at a first time according to the method of claim 18, wherein the patient-derived segment is obtained from the patient at about said time;

(b) determining anti-HBV drug susceptibility of the same patient at a later time; and

(c) comparing the anti-HBV drug susceptibilities determined in steps (a) and (b), wherein a decrease in anti-HBV drug susceptibility at the later time compared to the first time indicates development or progression of anti-HBV drug resistance in the patient.

28. The method of claim 1 wherein the resistance test vector comprises DNA encoding C, P, and X.

29. The method of claim 1 wherein the patient-derived segment comprises a P gene.

30. The method of claim 1 wherein the patient-derived segment comprises an HBV gene.

31. The method of claim 1 wherein the patient-derived segment comprises an HBV RT gene.

32. The method of claim 1 wherein the patient-derived segment comprises an HBV DNA polymerase gene.

33. The resistance test vector of claim 6 wherein the patient-derived segment comprises an HBV P gene.

34. A method for evaluating the biological effectiveness of a candidate anti-HBV drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment and an indicator gene into a host cell;

(b) culturing the host cell from step (a);

(c) measuring expression of the indicator gene in a target host cell, wherein the expression of the indicator gene is dependent upon the patient-derived segment; and

(d) comparing the expression of the indicator gene from step (c) with the expression of the indicator gene measured when steps (a)-(c) are carried out in the absence of the candidate anti-HBV drug compound, wherein a test concentration of the candidate anti-HBV drug compound is present at steps (a)-(c) at steps (b)-(c); or at step (c).

35. The method of claim 34 wherein the resistance test vector comprises DNA encoding HBV P protein.

36. The method of claim 34 wherein the patient-derived segment comprises an HBV gene.

37. A method for determining susceptibility for an anti-HBV drug comprising:

(a) introducing a resistance test vector comprising a patient-derived segment and an indicator into a host cell;

(b) culturing the host cell from (a);

(c) measuring the indicator in a target host cell, wherein a change in the indicator is dependent upon the patient-derived seqment; and

(d) comparing the measurement of the indicator from (c) with the measurement of the indicator when steps (a)-(c) are carried out in the absence of the anti-HBV drug, wherein a test concentration of the anti-viral drug is present at steps (a)-(c); at steps (b)-(c); or at step (c).

38. The method of claim 37 wherein the indicator comprises a DNA structure.

39. The method of claim 37 wherein the indicator comprises a RNA structure.

40. A method for evaluating the biological effectiveness of a candidate anti-HBV drug compound comprising:

(a) introducing a resistance test vector comprising a patient-derived segment and an indicator into a

(b) culturing the host cell from step (a);

(c) measuring the indicator in a target host cell, wherein a change in the indicator is dependent upon the patient-derived segment; and comparing the measurement of the indicator from step(c) with the measurement of the indicator measured when steps (a)-(c) are carried out in the absence of the candidate anti-HBV drug compound, wherein a test concentration of the candidate anti-viral drug compound is present at steps (a)-(c); at steps(b)-(c); or at step (c).

41. The method of claim 40 wherein the indicator comprises a DNA structure.

42. The method of claim 40 wherein the indicator comprises a RNA structure.

Details for Patent 6,242,187

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2016-01-29
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2016-01-29
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2016-01-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.